JNJ's Tremfya Gets EU Approval for Pediatric Plaque Psoriasis

Key Takeaways The EC approved Tremfya for patients aged 6-17 years with plaque psoriasis needing systemic therapy.The PROTOSTAR study met PASI 75 and IGA 0/1 endpoints at 16 weeks.Tremfya drove JNJ sales growth, generating $3.6B in the first nine months of 2025, up 31% year over year.Johnson & Johnson (JNJ) announced that the European Commission (EC) has approved an expanded use of its blockbuster psoriasis drug, Tremfya, in children. Tremfya is now approved to treat pediatric and adolescent patients (aged ...